LLY

713.66

-0.21%↓

JNJ

153.02

+0.33%↑

ABBV

183.38

+0.57%↑

NVO

67.22

-1.34%↓

UNH

295.3

-0.39%↓

LLY

713.66

-0.21%↓

JNJ

153.02

+0.33%↑

ABBV

183.38

+0.57%↑

NVO

67.22

-1.34%↓

UNH

295.3

-0.39%↓

LLY

713.66

-0.21%↓

JNJ

153.02

+0.33%↑

ABBV

183.38

+0.57%↑

NVO

67.22

-1.34%↓

UNH

295.3

-0.39%↓

LLY

713.66

-0.21%↓

JNJ

153.02

+0.33%↑

ABBV

183.38

+0.57%↑

NVO

67.22

-1.34%↓

UNH

295.3

-0.39%↓

LLY

713.66

-0.21%↓

JNJ

153.02

+0.33%↑

ABBV

183.38

+0.57%↑

NVO

67.22

-1.34%↓

UNH

295.3

-0.39%↓

Search

Day One Biopharmaceuticals Inc

Cerrado

SectorSalud

6.27 0.32

Resumen

Variación precio

24h

Actual

Mínimo

6.11

Máximo

6.31

Métricas clave

By Trading Economics

Ingresos

30M

-36M

Ventas

1.6M

31M

BPA

-0.35

Margen de beneficio

-117.018

Empleados

181

EBITDA

24M

-40M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 meses

+372.57% upside

Dividendos

By Dow Jones

Próximas Ganancias

29 jul 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

-147M

657M

Apertura anterior

5.95

Cierre anterior

6.27

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

Day One Biopharmaceuticals Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

23 may 2025, 20:33 UTC

Adquisiciones, fusiones, absorciones

Salesforce in Talks to Buy Informatica, Bloomberg Reports, Citing Sources

23 may 2025, 21:57 UTC

Acciones populares

Stocks to Watch: Apple, Booz Allen, Constellation Energy, Intuit -- WSJ

23 may 2025, 21:15 UTC

Principales Noticias

Trump Threatens Fresh Tariffs on EU, iPhones and Rival Devices -- 4th Update

23 may 2025, 21:04 UTC

Adquisiciones, fusiones, absorciones

Real-Estate Broker Douglas Elliman Could See Takeover Battle After Report of Bid -- Barrons.com

23 may 2025, 20:56 UTC

Principales Noticias
Adquisiciones, fusiones, absorciones

Salesforce Back in Deal Talks With Informatica -- WSJ

23 may 2025, 20:51 UTC

Principales Noticias

Boeing in Tentative Agreement to Pay $1.1 Billion to Avoid Trial for 737 MAX Crashes -- WSJ

23 may 2025, 20:50 UTC

Charlas de Mercado

Auto & Transport Roundup: Market Talk

23 may 2025, 20:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

23 may 2025, 20:41 UTC

Principales Noticias

Stocks Fall on Tariff Broadside, After Week of Bond Market Agita -- WSJ

23 may 2025, 20:28 UTC

Principales Noticias

Trump Threatens EU With 50% Tariffs, Takes Aim at Apple; Nasdaq Drops -- WSJ

23 may 2025, 20:06 UTC

Principales Noticias

Trump Threatens Fresh Tariffs on EU, iPhones and Rival Devices -- 5th Update

23 may 2025, 20:06 UTC

Adquisiciones, fusiones, absorciones

Salesforce Stock Drops, Informatica Soars. A Deal May Be Back on the Table. -- Barrons.com

23 may 2025, 19:50 UTC

Principales Noticias

Trump's Tariffs: Where Things Stand -- 16th Update

23 may 2025, 19:28 UTC

Adquisiciones, fusiones, absorciones

Trump on Truth Social: 'Bulk of That Investment Will Occur in the Next 14 Months'

23 may 2025, 19:28 UTC

Adquisiciones, fusiones, absorciones

Trump on Truth Social: 'This Will Be a Planned Partnership Between United States Steel and Nippon Steel'

23 may 2025, 19:27 UTC

Adquisiciones, fusiones, absorciones

Trump on Truth Social: 'Proud to Announce That, After Much Consideration and Negotiation, US Steel Will REMAIN in America'

23 may 2025, 19:20 UTC

Charlas de Mercado

Crude Futures Post Modest Weekly Losses -- Market Talk

23 may 2025, 19:18 UTC

Charlas de Mercado

U.S. Natural Gas Futures End Week Unchanged -- Market Talk

23 may 2025, 18:57 UTC

Principales Noticias

Trump Threatens Fresh Tariffs on EU, iPhones and Rival Devices -- 4th Update

23 may 2025, 18:54 UTC

Principales Noticias

Trump Threatens Fresh Tariffs on EU, iPhones and Rival Devices -- Update

23 may 2025, 18:53 UTC

Principales Noticias
Adquisiciones, fusiones, absorciones

McDonald's Bids Goodbye to CosMc's, Its Space Alien-Themed Spinoff -- WSJ

23 may 2025, 18:52 UTC

Adquisiciones, fusiones, absorciones

DDC Enterprise Issues 254,333 Class A Ordinary Shrs in Exchange for 21 BTC, Valued at About $2.28M in Current Market Price

23 may 2025, 18:13 UTC

Charlas de Mercado

Market Talk Roundup: Latest on U.S. Politics

23 may 2025, 18:13 UTC

Charlas de Mercado

Gold Trades Higher on Reminder of Risk -- Market Talk

23 may 2025, 18:00 UTC

Principales Noticias

Apple's Stock Still Not Pricing in Trump's Demands - Heard on the Street -- WSJ

23 may 2025, 17:51 UTC

Charlas de Mercado
Ganancias

Workday Sees Higher Bar for Guidance -- Market Talk

23 may 2025, 17:42 UTC

Principales Noticias

Dow Drops, Trump Threatens EU With 50% Tariffs, Takes Aim at Apple -- WSJ

23 may 2025, 17:39 UTC

Charlas de Mercado

U.S. Oil Rig Count Falls to Lowest Level Since November 2021 -- Market Talk

23 may 2025, 17:07 UTC

Principales Noticias

Trump's Tariffs: Where Things Stand -- 15th Update

23 may 2025, 17:04 UTC

Charlas de Mercado
Ganancias

Workday Appears to Have Upside Potential on Conservative Outlook -- Market Talk

Comparación entre iguales

Cambio de precio

Day One Biopharmaceuticals Inc Esperado

Precio Objetivo

By TipRanks

372.57% repunte

Estimación a 12 meses

Media 29.63 USD  372.57%

Máximo 40 USD

Mínimo 20 USD

De acuerdo con 9 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Day One Biopharmaceuticals Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

9 ratings

8

Comprar

1

Mantener

0

Vender

Puntuación técnica

By Trading Central

6.26 / 7.47Soporte y Resistencia

Corto Plazo

Very Strong Bearish Evidence

Medio plazo

Bullish Evidence

Largo Plazo

Bearish Evidence

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Day One Biopharmaceuticals Inc

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.